AVR anteris technologies global corp.

Ann: Montefiore enrolls Patients in US Early Feasibility Study, page-7

  1. 2,560 Posts.
    lightbulb Created with Sketch. 356
    All the primary and secondary outcome measures are 30 day with only "other" at 1 year. Does anyone know if "other" must be achieved for fda approval of this trial or would it be just primary and secondary outcomes?
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.05
Change
0.200(4.12%)
Mkt cap ! $78.29M
Open High Low Value Volume
$4.86 $5.05 $4.86 $10.89K 2.18K

Buyers (Bids)

No. Vol. Price($)
1 1212 $4.87
 

Sellers (Offers)

Price($) Vol. No.
$5.05 198 1
View Market Depth
Last trade - 13.02pm 28/07/2025 (20 minute delay) ?
AVR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.